 |
|
|
|
Wampole ELISA II |
| The Wampole ELISA II products comprise one of the broadest lines of ELISA tests in the industry. Over 60 assays are available across a broad menu,
including autoimmune disease, bladder cancer, cardiac risk assessment, enteric disease, infectious disease, STDs, and osteoporosis. |
| These test kits are capable of being run in a manual, semi-automated, or fully automated capacity with customized instrumentation packages available to
suit individual laboratory needs. |
| The Wampole ELISA II assays come in breakaway, removable test wells in a microplate format, with color-coded, ready-to-use reagents. |
| Most assays use interchangeable substrate, stop solution, and wash buffer. This uniformity of reagents allows for ease of automation with microtiter
processing systems. |
| With standard assay protocols for faster integration into the busy laboratory, our Infectious Disease ELISA products provide increased reliability and
run-to-run consistency. |
| The NMP22 ELISA test is the first and only test for the screening and monitoring of bladder cancer patients. |
| State-of-the-art monoclonal and monoclonal/polyclonal antibody-based technology is available in the enteric disease line of products. |
| Wampole ELISA II kits provide flexible testing, with simple procedures, a broad menu, and confidence in the results. |
SAVe Diluent™ for added confidence—only found in Wampole ELISA II assays |
| Other advanced technology exclusive to Wampole ELISA II tests is Wampole SAVe Diluent™, a sample addition verification system that assures no
well has been missed. By changing color from yellow to purple, it is a visual place keeper when preparing manual assays and a rapid verifier of proper instrument performance when running
automated platforms. |
| |
